Jennifer Cohen
Family Medicine · Dallas, TXNPI 1588808521
Payments from drug & device makers
Across 101 payments — averaging $14.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$221
- AbbVie$176
- Amgen$165
- Gilead$138
- Boehringer Ingelheim$112
- AstraZeneca$110
- plus $533 from 13 others
What the payments were for
- Food & beverage$1,454100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 19 | $221 |
| AbbVie | 11 | $176 |
| Amgen | 12 | $165 |
| Gilead | 9 | $138 |
| Boehringer Ingelheim | 7 | $112 |
| AstraZeneca | 8 | $110 |
| GSK | 7 | $107 |
| Viiv Healthcare Company | 4 | $81 |
| Astellas Pharma US Inc | 5 | $72 |
| Amarin Pharma, Inc. | 3 | $62 |
| Strongbridge US Inc. | 2 | $31 |
| Sanofi-aventis U.S. LLC | 2 | $29 |
| Teva Pharmaceuticals USA, Inc. | 2 | $27 |
| Pfizer | 2 | $26 |
| Novartis | 2 | $24 |
| Arbor Pharmaceuticals, Inc. | 2 | $24 |
| Lilly USA, LLC | 2 | $22 |
| Melinta Therapeutics, LLC | 1 | $19 |
| Johnson & Johnson | 1 | $11 |
How this compares
$1,454 in reported general payments places this provider in the 65th percentile of 8,760 family medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 34 | $59,421 |
| OzempicSemaglutide | 18 | $40,624 |
| JardianceEmpagliflozin | 24 | $34,552 |
| MyrbetriqMirabegron | 26 | $20,435 |
| JanuviaSitagliptin Phosphate | 11 | $18,075 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $16,770 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $11,863 |
| Aimovig AutoinjectorErenumab-Aooe | 12 | $9,066 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $3,912 |
| Atorvastatin Calcium | 158 | $1,484 |
| Gabapentin | 76 | $1,399 |
| Diclofenac Sodium | 30 | $1,142 |
| Duloxetine Hcl | 43 | $1,109 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 11 | $1,032 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 40 | $1,025 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $221 | $100,04552 claims |
| Boehringer IngelheimJardiance | $112 | $34,55224 claims |
| Astellas Pharma US IncMyrbetriq | $72 | $20,43526 claims |
| GSKTrelegy Ellipta | $107 | $16,77018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Dallas
- Thomas KingDallas$12M
- Jennifer ZonDallas$5.9M
- Chrisette DharmagunaratneDallas$5.6M
- Michele ReynoldsDallas$3.8M
- Shiwali RaiDallas$2.8M
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.